Lactobacilli reduce recurrences of vaginal candidiasis in pregnant women: a randomized, double-blind, placebo-controlled study

Ang XY 1 , Chung FY 1 , Lee BK 1 , Azhar SNA 2 , Sany S 3 , Roslan NS 2 Show all authors , Ahmad N 4 , Yusof SM 5 , Abdullah N 6 , Nik Ab Rahman NN 7 , Abdul Wahid N 8 , Deris ZZ 2 , Oon CE 9 , Wan Adnan WF 2 , Liong MT 1

Affiliations 

  • 1 School of Industrial Technology, Universiti Sains Malaysia, Penang, Malaysia
  • 2 School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
  • 3 Advanced Medical and Dental Institute, Universiti Sains Malaysia, Penang, Malaysia
  • 4 Kota Bharu Health Clinic, Ministry of Health Malaysia, Kelantan, Malaysia
  • 5 Kubang Kerian Health Clinic, Ministry of Health Malaysia, Kelantan, Malaysia
  • 6 Pengkalan Chepa Health Clinic, Ministry of Health Malaysia, Kelantan, Malaysia
  • 7 Wakaf Che Yeh Health Clinic, Ministry of Health Malaysia, Kelantan, Malaysia
  • 8 Sejahtera Centre, Universiti Sains Malaysia, Penang, Malaysia
  • 9 Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia
J Appl Microbiol, 2021 May 22.
PMID: 34022103 DOI: 10.1111/jam.15158

Abstract

AIMS: The aim of this study was to investigate the effects of lactobacilli strains in preventing the recurrences of vaginal candidiasis (VC) in 78 pregnant women with VC (lactobacilli, n = 39; placebo, n = 39) and the potential benefits on quality of life.

METHODS AND RESULTS: The lactobacilli putative probiotic (SynForU-HerCare; two capsules/day of 9·5 log CFU per capsule) or placebo was administered for 8-weeks in a randomized, double-blind, placebo-controlled study. Subjects were assessed for vaginal and gut health conditions at baseline, week-4 and week-8 via questionnaires. The vulvovaginal symptom questionnaire not only covered aspects pertaining to vulvovaginal symptoms but also the quality of life impacts such as emotional, social and sexual. The administration of lactobacilli reduced symptoms of irritation (P = 0·023) and discharge (P = 0·011) starting week-4 and continued after week-8 (P 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications